Weixia Li

3.6k citations
161 papers · 2.5k indexed · h-index 25

Impact in

Papers in

Weixia Li

151 papers receiving 2.5k citations

Peers

Weixia Li
Comparison fields: 5 of 169
  • Complementary and alternative medicine 423
  • Hepatology 301
  • Pharmacology 249
  • Critical Care and Intensive Care Medicine 90
  • Developmental Neuroscience 54
Replace Liying Wang with:
Liying Wang China
Yi Wang China
Jing Li China
Zhao China
Jia Chen United States
Miao Zhang China
Shuling Wang China
Aristides Tsatsakis Greece
Zhiyong Zhang China
Cheng Zhang China
Weixia Li relative to Liying Wang China Liying Wang's profile →
Citations per field
00.5×3.0×
Liying Wang · 1×
Citations per year

Countries citing papers authored by Weixia Li

Since Specialization
Citations

This map shows the geographic impact of Weixia Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weixia Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weixia Li more than expected).

Fields of papers citing papers by Weixia Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weixia Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weixia Li. The network helps show where Weixia Li may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Weixia Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Weixia Li Line = papers co-authored together Weixia Li links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 20250
3 20251
4 20251
5 20252
6 20241
7 20240
8 202416
9 20230
10 20236
11 202315
12 20231
13 20232
14 20232
15 20222
16 202211
17 202021
18 202012
19 201824
20 201013

About Weixia Li

Weixia Li is a scholar working on Complementary and alternative medicine, Hepatology, Pharmacology, Pharmacology and Biological Psychiatry, having authored 161 papers that have together received 2.5k indexed citations. Recurring topics across this work include Traditional Chinese Medicine Analysis (30 papers), Traditional Chinese Medicine Studies (16 papers), Liver Disease Diagnosis and Treatment (16 papers), Hepatitis B Virus Studies (14 papers), Metabolomics and Mass Spectrometry Studies (12 papers), Hepatitis C virus research (10 papers), Ginseng Biological Effects and Applications (10 papers) and Flavonoids in Medical Research (9 papers). The work is most often cited by research in Complementary and alternative medicine (423 citations), Hepatology (301 citations), Pharmacology (249 citations), Critical Care and Intensive Care Medicine (90 citations) and Developmental Neuroscience (54 citations). Weixia Li has collaborated with scholars based in China, United States and Germany. Frequent co-authors include Yuping Tang, Jin‐Ao Duan, Kemin Chen, Yuxian Huang, Qiang Li, Xiao Lin, Peijie Lv, Jianying Li, Yanyan Chen and Jianming Guo. Their work appears in journals such as Scientific Reports, Journal of Pharmaceutical and Biomedical Analysis, Journal of Ethnopharmacology, Oncotarget and Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026